Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

New Drug and Possible New Toxicity – Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors

(2016) FAISAL INAYAT et al.   ANTICANCER RESEARCH

A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform

(2016) Y Choi et al.   PHARMACOGENOMICS JOURNAL

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

(2015) Toshirou Nishida et al.   Gastric Cancer

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

(2014) Dong-Hoe Koo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

(2014) Q Zheng et al.   PHARMACOGENOMICS JOURNAL

Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants

(2013) Katie M. O'Brien et al.   PLoS One

Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies

(2012) Bo Gao et al.   JOURNAL OF CLINICAL ONCOLOGY

The safety profile of imatinib in CML and GIST: long-term considerations

(2011) Eirini Thanopoulou et al.   ARCHIVES OF TOXICOLOGY

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors

(2011) Steven Lane et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Moving towards dose individualization of tyrosine kinase inhibitors

(2010) Heinz-Josef Klümpen et al.   CANCER TREATMENT REVIEWS

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

(2010) K. Eechoute et al.   CLINICAL CANCER RESEARCH

Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib

(2010) Changhoon Yoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate

(2009) Jonathan C. Trent et al.   CANCER

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients

(2009) J. Du et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

(2008) N Widmer et al.   BRITISH JOURNAL OF CANCER

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

(2008) Roos L. Oostendorp et al.   INVESTIGATIONAL NEW DRUGS

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY